The SQSTM1/p62 UBA domain regulates Ajuba localisation, degradation and NF-κB signalling function.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 30 07 2020
accepted: 21 10 2021
entrez: 4 11 2021
pubmed: 5 11 2021
medline: 7 1 2022
Statut: epublish

Résumé

The LIM-domain containing protein Ajuba and the scaffold protein SQSTM1/p62 regulate signalling of NF-κB, a transcription factor involved in osteoclast differentiation and survival. The ubiquitin-associated domain of SQSTM1/p62 is frequently mutated in patients with Paget's disease of bone. Here, we report that Ajuba activates NF-κB activity in HEK293 cells, and that co-expression with SQSTM1/p62 inhibits this activation in an UBA domain-dependent manner. SQSTM1/p62 regulates proteins by targeting them to the ubiquitin-proteasome system or the autophagy-lysosome pathway. We show that Ajuba is degraded by autophagy, however co-expression with SQSTM1/p62 (wild type or UBA-deficient) protects Ajuba levels both in cells undergoing autophagy and those exposed to proteasomal stress. Additionally, in unstressed cells co-expression of SQSTM1/p62 reduces the amount of Ajuba present in the nucleus. SQSTM1/p62 with an intact ubiquitin-associated domain forms holding complexes with Ajuba that are not destined for degradation yet inhibit signalling. Thus, in situations with altered levels and localization of SQSTM1/p62 expression, such as osteoclasts in Paget's disease of bone and various cancers, SQSTM1/p62 may compartmentalize Ajuba and thereby impact its cellular functions and disease pathogenesis. In Paget's, ubiquitin-associated domain mutations may lead to increased or prolonged Ajuba-induced NF-κB signalling leading to increased osteoclastogenesis. In cancer, Ajuba expression promotes cell survival. The increased levels of SQSTM1/p62 observed in cancer may enhance Ajuba-mediated cancer cell survival.

Identifiants

pubmed: 34735553
doi: 10.1371/journal.pone.0259556
pii: PONE-D-20-23722
pmc: PMC8568271
doi:

Substances chimiques

NF-kappa B 0
SQSTM1 protein, human 0
Sequestosome-1 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0259556

Déclaration de conflit d'intérêts

No authors have competing interests.

Références

J Clin Invest. 2008 May;118(5):1858-66
pubmed: 18382763
J Bone Miner Res. 2006 Jul;21(7):1136-45
pubmed: 16813535
J Biol Chem. 2003 Jan 10;278(2):1220-8
pubmed: 12417594
Curr Osteoporos Rep. 2014 Sep;12(3):263-71
pubmed: 24988994
Trends Biochem Sci. 2007 Feb;32(2):95-100
pubmed: 17174552
J Cell Biol. 2005 Feb 28;168(5):813-24
pubmed: 15728191
J Biol Chem. 2007 Jan 5;282(1):39-48
pubmed: 17092936
FEBS J. 2019 Jan;286(1):8-23
pubmed: 30499183
Mol Cell Biol. 2005 May;25(10):4010-22
pubmed: 15870274
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2938-43
pubmed: 20133701
Oncogene. 2008 Jan 10;27(3):274-84
pubmed: 17621269
J Cell Physiol. 2018 Jun;233(6):4606-4617
pubmed: 29219182
Am J Pathol. 2006 Aug;169(2):503-14
pubmed: 16877352
Biochem Biophys Res Commun. 2005 Mar 18;328(3):728-38
pubmed: 15694407
J Bone Miner Res. 2009 Apr;24(4):632-42
pubmed: 19049332
Dev Cell. 2004 Feb;6(2):303-9
pubmed: 14960283
Bone. 2013 Feb;52(2):699-706
pubmed: 23117207
Curr Biol. 2010 Apr 13;20(7):657-62
pubmed: 20303269
Gene. 2018 Feb 20;644:148-154
pubmed: 29126926
Endocr Rev. 2013 Aug;34(4):501-24
pubmed: 23612225
Nat Rev Mol Cell Biol. 2004 Nov;5(11):920-31
pubmed: 15520811
Mol Cell Biol. 2005 May;25(10):3956-66
pubmed: 15870270
Cell Adh Migr. 2013 May-Jun;7(3):283-7
pubmed: 23590879
J Bone Miner Res. 2009 Jul;24(7):1216-23
pubmed: 19257822
J Bone Metab. 2014 May;21(2):85-98
pubmed: 25025000

Auteurs

Melanie A Sultana (MA)

Neurogenetics Laboratory, Harry Perkins Institute for Medical Research, University of Western Australia, Nedlands, Australia.
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

Carmel Cluning (C)

Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

Wai-Sin Kwong (WS)

Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

Nicole Polain (N)

Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.

Nathan J Pavlos (NJ)

School of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.

Thomas Ratajczak (T)

Neurogenetics Laboratory, Harry Perkins Institute for Medical Research, University of Western Australia, Nedlands, Australia.
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

John P Walsh (JP)

Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Medical School, University of Western Australia, Crawley, Western Australia, Australia.

Jiake Xu (J)

School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia.

Sarah L Rea (SL)

Neurogenetics Laboratory, Harry Perkins Institute for Medical Research, University of Western Australia, Nedlands, Australia.
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Western Australia, Australia.
Perron Institute for Neurological and Translational Science, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Nedlands, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH